Palatin Technologies Inc PTN.A :
* PALATIN TECHNOLOGIES, INC. REPORTS SECOND QUARTER FISCAL
YEAR
2020 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
* Q2 LOSS PER SHARE $0.02
* DRY EYE DISEASE PHASE 2 STUDY TO COMMENCE Q1 2020
* PALATIN TECHNOLOGIES- AMAG'S PLANNED DIVESTITURE OF
VYLEESI IS
BASED ON CHANGE IN STRATEGY, "AND IS NOT A RESULT OF VYLEESI
LAUNCH PERFORMANCE TO DATE"
* PALATIN TECHNOLOGIES - DATA FROM DRY EYE DISEASE PHASE 2
STUDY
EXPECTED IN Q4 2020 & ULCERATIVE COLITIS TRIAL DATA EXPECTED IN
MID-CALENDAR YEAR 2021
* QTRLY LICENSE AND CONTRACT REVENUE $20,610
Source text for Eikon: ID:nPn3ZyRJLa
Further company coverage: PTN.A